Holley Group

Holley Group

Holley Group began in 1970 as a maker of electrical instruments in Hangzhou before Wang Licheng steered it into two distinct lines of business: pharmaceutical manufacturing and overseas industrial park development. The firm's drug portfolio centers on Kunming Pharmaceuticals and Wuhan Jianmin Pharmaceuticals, domestic subsidiaries that anchor a supply chain extending from active pharmaceutical ingredients to finished traditional Chinese medicines. The group's artemisinin patent portfolio — protecting the core compound used in artemisinin-based combination therapies for malaria — gives it a structural position in global public health procurement that few private Chinese enterprises hold. Beyond pharmaceuticals, Holley deploys capital as a developer and anchor investor in cross-border industrial zones. The Thai-Chinese Rayong Industrial Zone in Thailand, the Hofusan Industrial Park in Nuevo León, Mexico — developed with partners Futong Group and the Santos family — and the Great Silk Road Industrial Technopark in Uzbekistan form a network that supports Chinese manufacturers establishing production outside mainland China. These parks are not passive real estate plays; Holley operates them as long-term infrastructure platforms, leasing factory shells and providing logistics, utilities, and regulatory interface for tenant firms. The mixed-use 181 Maker Land project in Hangzhou rounds out the property book. Wang Licheng leads the group as Chairman, while his external roles reinforce the firm's dual identity as a commercial operator and a policy-adjacent institution. He chairs the China-Africa Business Council and sits on the standing committee of the All-China Federation of Industry and Commerce, placing Holley at the intersection of Chinese outbound investment policy and private-sector execution. The group maintains a philanthropic arm, the Greencare Foundation, though its scale and programs are not publicly detailed. Holley's structural differentiator is its unusual blend of an artemisinin-dominated pharmaceutical intellectual property moat and a physical network of state-aligned but privately developed overseas industrial parks. This pairing — one intangible and global, the other concrete and corridor-specific — makes the group less a conventional family office and more a hybrid industrial holding company with a cross-border development mandate.